Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK-REALM
NCT04395092Phase 2Withdrawn
- Sponsor
- Kiadis Pharma
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of expanded haploidentical NK cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Kiadis Pharma. Planned start Nov 2020; status: withdrawn.
02
Drugs
expanded haploidentical NK cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04395092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395092.